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INTRODUCTION 
 
             "All pain is per se and especially in excess, destructive 
and ultimately fatal in its nature and effects."  
                                                          James Young Simpson (1811 – 1870) 
   "Labour results in severe pain for many women. There is no other 
circumstance where it is considered acceptable for a person to 
experience untreated severe pain, amenable to safe intervention, while 
under a physician's care. Maternal request is a sufficient medical 
indication for pain relief during labour."    Labour results in severe 
pain for most women. When pain relief is available, the vast majority 
of women request and receive analgesic medication for the treatment 
of labour pain. The ideal labour analgesic technique should 
dramatically reduce the pain of labour, while allowing the parturient to 
actively participate in the birthing experience. In addition, it should 
have minimal effect on the foetus or the progress of labour. New 
labour analgesia techniques approach this goal. 
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   Of all the possible methods of pain relief which can be used in labour, 
neuraxial blockade (epidural, spinal, CSE, continuous spinal) provides the 
most effective and least depressant analgesia. Epidural analgesia via a 
catheter technique provides excellent pain relief and the ability to extend 
the duration of the block to match the duration of labour, but it is not 
"instant" in onset and may be associated with motor block. One-shot 
spinal analgesia using a lipid soluble opioid is rapid and simple, but is 
associated with a limited duration of action. The combination of epidural 
and spinal anaesthesia into one technique, termed "CSE" provides the 
advantages of a spinal (speed of onset, lack of motor block) with the 
additional flexibility of renewal with an epidural catheter. 
      Combination of low dose of local anaesthetics and opioid dramatically 
reduce the incidence of lower limb motor blockade, enabling mothers to 
walk, sit or stand upright. This was impossible with traditional epidurals 
using high intermittent boluses of 0.25% bupivacaine which cause a high 
incidence of motor block in the legs.  
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AIM 
       To compare combined spinal epidural analgesia with conventional 
epidural analgesia using fentanyl-bupivacaine in alleviating labour pain. 
       To study their effects on the mother and the fetus. 
       To study their effects on progress of labour and delivery. 
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HISTORY OF OBSTETRIC ANALGESIA 
1. In 1847, shortly after the first public demonstration of ether 
anaesthesia, James Young Simpson used diethyl ether for labour 
analgesia. 
2. Repeated injections of large doses of morphine and scopolamine - 
the technique, called “Da¨mmerschlaf” or “twilight sleep,” often 
led to severe maternal and neonatal respiratory depression. 
3. In 1847, Walter Channing stated that placental transfer of ether 
was negligible, as he could not detect an odour of ether after 
having cut the umbilical cord. Although the significance of 
placental drug transfer was recognized in 1877 when Paul Zweifel 
proved the presence of chloroform in umbilical vessels of 
newborns, this knowledge did not alter clinical practice over the 
next decades.         
4. One hundred years ago, in July 1900, the obstetrician Oscar Kreis, 
from Switzerland was the first to recognize the advantages of 
regional analgesia in obstetrics, when applying spinal cocaine to 
ameliorate labour pain in six parturients with a fully dilated          
cervix. 
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5. 1923, the first reports on combined spinal-epidural anaesthetics 
(CSE) in surgical patients appeared, initially as a combined single-
shot technique. 
6. The basis of regional blocks for labour analgesia was founded on 
neuroanatomical principles, when Cleland described the sensory 
innervation of the uterus in 1933. 
7. 1949 Bonica implemented round the clock obstetric services in 
US. 
8. The negative experiences with regional anaesthesia resulted in an 
abandonment of pain relief in obstetrics until the 1950s, a period 
often described as the “dark ages of obstetric anaesthesia”. It was 
during this time that “natural childbirth” and “psychoprophylaxis” 
were widely advocated to avoid serious anaesthesia-related side 
effects. 
9. In the following years, lumbar epidural analgesia gained more 
popularity because the success rate was high, local anaesthetic 
requirements were reduced, the onset of analgesia was faster,        
and the catheter was positioned in a place considered                          
less prone for infection.   
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10. In 1962, Lee introduced the first catheter with a closed tip and a 
lateral hole to reduce trauma on insertion. 
11. In 1953 the anaesthesiologist V. A. Apgar introduced a score to 
evaluate the newborn based on physiologic variables, thus creating 
a simple, although not always reliable, tool to detect the effects of 
anaesthetics on the newborn. 
12. The discovery of spinal opioid receptors in the late 1970s led to a 
widespread use of epidurally and intrathecally administered 
opioids, and the combination of opioids and dilute local 
anaesthetics in providing labour pain relief became standard 
practice. Using these dilute solutions, Chestnut et al. and 
subsequently Vertommen et al. demonstrated that epidural 
analgesia did not necessarily increase the incidence of instrumental 
deliveries. 
13. Patient-controlled epidural analgesic techniques, which were 
shown to reduce local anaesthetic requirements by 30% in 
comparison with continuous epidural infusions. 
14. A potential advantage of CSE is the possibility to ambulate 
(walking epidural) and has been demonstrated in several trials. 
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Parturients appreciate not being confined to their beds during the 
first stage of labour. 
15. The first epidural analgesia was done by Leonard. J.Corning in 
1885 inadvertently. Lumbar dural puncture was introduced in 1891 
by Wytner in England and Quincke in Germany. Karl Gustav 
August Bier was the first to do a planned spinal anaesthetic in 
1898. 
16. 1937, Soresi introduced the single space – single needle technique 
of CSEA. 
17. 1979, Curelaru, Swedish anaesthesiologist, introduced the double 
space – double needle technique of CSEA. 
18. 1982 – Coates from England and Mumtaz, Daz & Kuz from 
Sweden, described the needle through needle technique of CSEA 
independently. 
19. 1990 - Introduction of Eldor needle. 
20. Eldor, Coombs & Torrieri technique – Introduction in 1988.       
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PAIN PATHWAYS IN LABOUR AND DELIVERY: 
Pain pathways during labour and delivery 
 Uterus and cervix - afferent impulses are transmitted via the Aδ and 
C fibres which travel with sympathetic nerves via the hypogastric plexus 
to enter the lumbar and lower thoracic parts of the sympathetic chain. 
Central connection to the spinal cord is via the dorsal root ganglion and 
lateral division of the posterior roots of T10-L1. Labour pains are 
therefore referred to the areas of skin supplied by these nerves i.e. the 
lower abdomen, loins and lumbo-sacral region. 
 Vagina and pelvic outlet - afferent transmission is also via Aδ and 
C fibres but with the parasympathetic bundle in the pudendal nerves 
(S2,3,4). There is also a minor contribution from the ilio-inguinal, genito-
femoral and the perforating branch of the posterior cutaneous nerve of 
thigh. 
 It is important to appreciate that pain sensitive structures in the 
pelvis are also involved, i.e. the adnexi, the pelvic parietal peritoneum, 
bladder, urethra, rectum and the roots of the lumbar plexus. Therefore L2 
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to S5 must  be blocked. There is an overlap and pain relief is not a simple 
matter of blocking T10 to L1 for the first stage and S2, 3, 4 for the second 
stage of labour. 
CONSEQUENCES OF UNRELIEVED PAIN IN LABOUR  
 The unrelieved pain in labour produces increased plasma cortisol 
and catecholamine concentrations which may be responsible for the 
reduction in utero placental blood flow. Pain induced hyperventilation and 
hypocapnia can be severe enough in painful labour to produce tetany and 
it also reduces the uteroplacental blood flow. The respiratory alkalosis 
further impairs foeto-maternal gas exchange by shifting the oxygen 
dissociation curve to the left.  Foetal PaO2 may fall. When the above 
stress is removed by effective pain relief all return to normal.   
EFFECTS OF LABOUR ANALGESIA USING ABOVE 
TECHNIQUES ON THE MOTHER: 
RESPIRATION:                                                                                                                  
 Uncomplicated CSEA/epidural analgesia has no direct effect on the 
respiratory center and the changes in pulmonary function caused by it are 
clinically insignificant. When sensory blockade is at T9 or T10 segment, 
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there is no weakness of intercostals or abdominal muscles. Even if lower 
intercostals and abdominal muscles are weakned or paralysed , there is no 
decrease in pulmonary ventilation because the diaphragm and the 
unaffected intercostals muscles are able to compensate. If complete motor 
block extends above T7, there is significant reduction of the expiratory 
reserve volume and end tidal ventilation falls below the pulmonary 
closing volume resulting in pulmonary atelectasis and hypoxaemia. 
The beneficial effects on ventilation:                                                                                   
 During the normal uterine contractions as the frequency and 
intensity of uterine contractions progresses, moderate to severe pain acts 
as an intense stimulus to ventilation with consequent reduction in PaCO2 
(Respiratory alkalosis).This is followed by hypoventilation and reduction 
of maternal PaO2 and decreased Foetal PaO2 (Foetal hypoxia). 
CSEA/Epidural analgesia by eliminating pain prevents or counters the 
above changes and produces beneficial effects to both mother and fetus. 
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CIRCULATION:  
             During painful uterine contraction there is an increase in cardiac 
output and blood pressure. Above techniques by blunting the painful 
stimuli and neuroendocrine stress response to pain, reduce the degree of 
progressive increase in cardiac output and blood pressure. This decreases 
the myocardial workload and oxygen consumption. With the uppermost 
level of analgesia at T10, there is decrease in peripheral resistance, venous 
return and cardiac output.In normal parturient lying on their side, reflex 
cardiovascular mechanism counteract these effects and maintain blood 
pressure near normal levels. 
NEUROENDOCRINE RESPONSE: 
           Pain increases neuroendocrine stress hormones. CSEA/Epidural 
analgesia by blocking all nociceptive input and sympathetic effects, 
reduce the release of stress hormones thereby preventing untoward effects 
on the cardiovascular system and the progress of labour. It doesn’t 
decrease the Foetal catecholamines and beta-endorphin release. 
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ALIMENTARY FUNCTION:  
 CSEA/Epidural analgesia by interrupting the nociceptive barrage 
and sympathetic efferents to gastrointestinal tract decreases the magnitude 
of gastrointestinal inhibition and tends to increase the lower oesophageal 
sphincter tone. Intrathecal /Epidural opioids tends to delay gastric 
emptying. 
 ON THE FOETUS AND NEWBORN: 
         CSEA/ epidural analgesia stabilizes the maternal physiology though 
such mechanisms that include decreased maternal oxygen consumption, 
higher maternal PaO2, less maternal acidosis, and less catecholamine 
release, all providing for a favourable intrauterine environment. Neonates 
of mothers managed with properly placed CSEA/epidural analgesia did 
not manifest the neonatal depression.   Widespread use of segmental 
epidural analgesia entails the use of smaller dose of local anaesthetic and 
there is minimal or no adverse effects on the parameters that constitute the 
APGAR score. Non-ionised portion of local anaesthetic crosses the 
placental membranes but the percentage of bupivacaine that crosses the 
placenta -18% is less when compared with other local anaesthetics.                          
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Foetal tissue uptake of local anaesthetics will increase with increasing 
degrees of foetal acidosis .Foetal and maternal blood gases and acid base 
status during either low dose intermittent or continuous lumbar epidural 
analgesia was not significantly different from those without analgesia. 
Increase in uteroplacental blood flow and improvement in foetal acid base 
status following CSEA/epidural analgesia is due to relief of vasospasm of 
the uteroplacental circulation and elimination of sympathoadrenal activity.                           
It has no effect on foetal heart rate patterns and on neurobehavioural 
responses of neonate. 
ON UTERINE CONTRACTILITY: 
1) If maternal hypotension and hypovolemia are avoided and the 
mother assumes left lateral position, above techniques will not lead 
to a change in frequency or strength of uterine contractions 
2) Increased uteroplacental blood flow with CSEA/epidural analgesia 
itself may increase uterine action 
3) CSEA/ epidural analgesia normalizes the irregular contraction in 
inco-ordinate uterine action and speeds up labour.  
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ON THE STAGES OF LABOUR 
FIRST STAGE: The refined technique of CSEA/ EA has little or no 
effect on the progress of cervical dilatation and the duration of the first 
stage of uncomplicated labour. Care should be taken that the analgesia is 
initiated at the appropriate time with adequate preloading. The mother is 
kept in the left lateral position during intermittent bolus administration of 
drug and throughout labour so that maternal hypotension is avoided and 
uteroplacental blood flow is maintained. The first stage is divided into 
latent and active phases. The active phase has three identifiable 
component parts- an acceleration phase, a linear phase of maximum slope 
and a deceleration phase. The maximum cervical dilatation occurs during 
the active phase and the intensity of pain is also severe in this stage. 
LATENT PHASE: Initiation of CSEA/ EA or even excessive sedation 
during this phase decreases uterine activity and prolongs the labour. 
ACTIVE PHASE: CSEA/Epidural analgesia does not alter the overall 
rate of progress in the active phase of the first stage of normal labour. It 
may actually shorten the first stage of labour by abolishing anxiety. 
 15
SECOND STAGE: The effect of CSEA/ EA on the resistant and 
expulsive forces and hence on the duration of the second stage of labour 
depends on the technique used and obstetric management. 
 Continuous caudal or mid lumbar is associated with significantly 
prolonged second stage of labour and increased incidence of instrumental 
delivery.  
 The use of segmental epidural analgesia for the first stage and its 
extension to the sacral segments for the second stage and delivery with 
0.125 bupivacaine or 1% lignocaine still shows longer duration of second 
stage and increased incidence of instrumental delivery. The second stage 
is prolonged because- 
1) Block of the sensory roots S 2,3,4 obtunds the bearing down 
reflex. 
2) The partial block of the lower abdominal muscles weaken them 
thereby decreasing the maternal expulsive power. 
3) The associated weakening of the pelvic floor muscles delay the 
rotation of the presenting part during its descent through the 
pelvis and this also contributes to the delay in the second stage. 
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4)  CSCA Epidural analgesia interferes with Ferguson’s reflex and 
the release of oxytocin from the posterior pituitary in response to 
stretching of birth canal. This can be overcome by a routine use of 
oxytocin infusion especially in primipara.                                                                   
5) Delay in bearing down efforts until the presenting part is visible at 
the introitus is likely to prolong the second stage. But if foetal 
monitoring shows no distress and maternal distress is not allowed, 
it will decrease significantly the incidence of non-rotation and 
increase of the incidence of spontaneous delivery.                                                     
6) CSEA/epidural analgesia has beneficial effects in dysfunctional 
uterine contractions. It improves maternal and Foetal outcome. 
THIRD STAGE: Third stage is not affected by CSEA/EA. 
DELIVERY PROCESS: The optimal management of prolonged second 
stage of labour remains a confused area of thought and action. As the 
second stage is prolonged there is a tendency for the obstetricians to apply 
forceps early. But given sufficient time and in the absence of anatomical 
obstruction, the foetal head will rotate satisfactorily. If the mother is not 
allowed to bear down until the presenting part distends the perineum she 
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will have sufficient reserve of power and will to push effectively to 
accomplish a spontaneous delivery. If as delivery approaches, uterine 
activity appears not to be sufficient to maintain the steady onward 
progress of the presenting part, it can be supplemented by judicious 
administration of oxytocin. Crawford stresses that if there is no evidence 
of foetal distress and if the mother displays no sign of undue fatigue, there 
is no recognizable limit to the time which can be invested  in the delivery 
process.  
SPINAL EPIDURAL SPACE – IN PREGNANCY  
Epidural veins 
 The epidural venous plexus is a valveless system that 
communicates with the basivertebral vein, the intracranial sigmoid, 
occipital, and basilar venous sinuses and the azygos system. Drugs, air or 
other material injected into the epidural space can potentially reach the 
heart or brain directly through this route. Abdominal and thoracic veins 
connect with the venous plexus through the intervertebral foramina and 
transmit intraabdominal and intrathoracic pressure to the epidural space. 
Inferiorly, the venous plexus connects with the iliac veins through the 
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sacral venous plexus. Obstruction of the inferior vena cava in late 
trimester pregnancy can distend the epidural venous plexus, with 
important implications for spinal and epidural anaesthesia.                          
This increases the risk of intravascular cannulation with an epidural 
catheter.  
 It effectively decreases epidural space volume, allowing local 
anaesthetics to distribute more widely with resulting greater degrees of 
block. Exposure to greater vascular surface area also potentially increases 
the risk for local anaesthetic toxicity due to absorption from the epidural 
space. The constituents of cerebral spinal fluid (CSF) do not change 
during pregnancy but its volume is reduced due to compression from the 
epidural veins in the epidural space. The pressure of the CSF is therefore 
increased. Between contractions the pressure may be around 28 mm Hg 
but during painful contractions it may rise to as much as 70mmHg. It is 
therefore probably safer not to advance an epidural or spinal needle 
during contractions for risk of puncturing the dura and expulsion of CSF 
at high pressure. As a result of reduced volume of CSF drug dose 
requirement is reduced to one third on normal for neuraxial blocks in late 
pregnancy.     
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CONDITIONS ESSENTIAL FOR INITIATING SPINAL-
EPIDURAL ANALGESIA: 
1. The parturient should be in the active phase of labour and 
experiencing moderate pain during uterine contractions 
2. The contractions should be regular, of good intensity and occurring 
at intervals of 3 minutes or less and lasting 35-40 seconds or longer. 
3. The presenting part should be engaged in the pelvis. 
4. The cervix should be dilated 3 or 4 cm. 
INDICATIONS FOR SPINAL-EPIDURAL ANALGESIA: 
1. To relieve labour pains thereby reducing anxiety and apprehension in 
expectant mothers. 
2. Maternal factors – Trial of labour in high risk parturients  
    Congenital or acquired heart disease/Pregnancy induced hypertension / 
Essential hypertension and pulmonary hypertension/Endocrine disorders 
like diabetes/Renal and hepatic diseases/Pulmonary diseases like asthma 
and neurological disorders. 
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3. Foetal conditions 
Prematurity/Postmaturity/Multiple births/Breech deliveries and 
intra-uterine growth retardation. 
4. Obstetric conditions 
Prolonged labour due to primary cervical dystocia/Induction of 
labour/Forceps delivery/Multiple pregnancies and occipito-
posterior position. 
CONTRA-INDICATIONS FOR LUMBAR SPINAL-EPIDURAL 
ANALGESIA: 
Absolute: 
     Patient refusal / Infection at site of proposed puncture / coagulopathies 
/anatomical abnormalities like spina bifida, fused spine or AV 
malformations diagnosed at the lumbar vertebral column and severe 
hypovolemia from hemorrhage, dehydration or malnutrition. 
Relative: 
 Very early labour/Rapid or precipitous labour/Unco-operative 
patient/Uncontrolled pre-eclampsia, eclampsia, accidental hemorrhage 
and pre-existing neurological diseases. 
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COMPLICATIONS ANTICIPATED: 
 Systemic arterial hypotension, Systemic toxic effects due to local 
anaesthetics, Perforation of dura- postdural puncture headache, Total 
spinal anaesthesia due to accidental sub-arachanoid injection of large 
doses of local anaesthetics, Shearing of catheters, Local or epidural 
infection or possible abscess or extradural hematoma, Shivering, 
Neurological sequelae-backache, leg pain, numbness and weakness, 
Foetal or neonatal complications (Maternal hypotension, Excess amounts 
of local anaesthetic, Accidental Foetal local anaesthetic intoxication, 
Injection of local anaesthetic into Foetal scalp with caudal analgesia)  and 
Complications due to intrathecal/epidural opioids ( Pruritis, Nausea and 
vomiting, Urinary retention, Delayed respiratory depression and Sedation) 
PHARMACOLOGY: 
BUPIVACAINE: 
 It was first synthesized in Sweden by Ekenstam and his colleagues 
in 1957 and used clinically by L.J.Telivuo in 1963. 
 Chemical formula                  C18H28N20 
 Molecular mass                       288.43 g/mol 
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PHARMACOKINETIC DATA 
pKa   8.1  
Lipid solubility  28   Protein binding 95% 
Nonionised fraction at physiological pH     15% 
Onset of action                1-2 minutes (intrathecal)                                  
       15-20 minutes (epidural) 
Volume of distribution                                  73 litres 
Clearance of drug from plasma                   0.47 litres/minute 
Distribution half life – alpha                        2.7 minutes 
                                   - beta                        28 minutes 
Elimination half life                                   3.5 hours (adults), 8.1 hours 
(neonates) 
Metabolism                                                    Hepatic 
Excretion                                                        Renal, 4 to 10%  
Toxic concentration                                       >1.6 mcg/ml 
THERAPEUTIC CONSIDERATIONS 
Pregnancy          Category A 
Routes        - Spinal, epidural, caudal, regional nerve blocks, topical 
Maximum dose  - 3mg/kg with or without adrenaline 
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 Bupivacaine is chemically designated as 2-piperidinecarboxamide, 
1-butyl-N-(2, 6-dimethylphenyl)-, monohydrochloride, monohydrate.  
 Bupivacaine is related chemically and pharmacologically to the 
aminoacyl local anaesthetics. It is an amide type of local anaesthetic 
agent. It is a homologue of mepivacaine and is chemically related to 
lidocaine. All three of these anaesthetics contain an amide linkage 
between the aromatic nucleus and the amino or piperidine group. They 
differ in this respect from the procaine-type local anaesthetics, which have 
an ester linkage. Solutions should be stored at controlled room 
temperature 15-30°C (59-86°F) . Solutions containing epinephrine should 
be protected from light. 
Preservative free: MPF indicates single dose solutions that are Methyl 
Paraben Free . It is a sterile isotonic solution containing sodium chloride.                             
Mechanism of action 
 Bupivacaine binds to the intracellular portion of sodium channels 
and blocks sodium influx into nerve cells, which prevents depolarization. 
In general, the progression of anaesthesia is related to the diameter, 
myelination and conduction velocity of affected nerve fibers. Clinically, 
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the order of loss of nerve function is as follows: (1) pain, (2) temperature, 
(3) touch, (4) proprioception, and (5) skeletal muscle tone. Since pain 
transmitting nerve fibres tend to be thinner and either unmyelinated or 
lightly myelinated, the agent can diffuse more readily into them than into 
thicker and more heavily myelinated nerve fibres like touch, 
proprioception, etc. (Myelin is non-polar / lipophilic). 
 Developments 
 Levobupivacaine is the R (-)-enantiomer of bupivacaine, with a 
longer duration of action and produces less vasodilatation 
PHARMACOKINETICS:  
 The rate of systemic absorption of local anaesthetics is dependent 
upon the total dose and concentration of drug administered, the route of 
administration, the vascularity of the administration site and the        
presence or absence of epinephrine in the anaesthetic solution. A dilute 
concentration of epinephrine (1:200,000 or 5 mcg/mL) usually reduces the 
rate of absorption and peak plasma concentration, permitting the use of 
moderately larger total doses and sometimes prolonging the duration of 
action. The onset of action is rapid in pregnancy and anaesthesia is long 
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lasting. The duration of anaesthesia is significantly longer. It has also 
been noted that there is a period of analgesia that persists after the return 
of sensation, during which time the need for strong analgesics is reduced.                            
 Local anaesthetics appear to cross the placenta by passive diffusion. 
The rate and degree of diffusion is governed by - the degree of plasma 
protein binding, the degree of ionization and the degree of lipid solubility.  
 Foetal/maternal ratios of local anaesthetics appear to be inversely 
related to the degree of plasma protein binding, because only the free, 
unbound drug is available for placental transfer. Bupivacaine with a high 
protein binding capacity (95%) has a low Foetal/maternal ratio (0.2 to 
0.4). Depending upon the route of administration, local anaesthetics are 
distributed to some extent to all body tissues, with high concentrations 
found in highly perfused organs such as the liver, lungs, heart and brain.  
 After injection for caudal, epidural, or peripheral nerve block in 
man, peak levels of bupivacaine in the blood are reached in 30 to 45 
minutes, followed by a decline to insignificant levels during the next three 
to six hours. Various pharmacokinetic parameters of the local anaesthetics 
can be significantly altered by the presence of hepatic or renal disease, 
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addition of epinephrine, factors affecting urinary pH, renal blood flow, the 
route of drug administration, and the age of the patient. The half-life of 
bupivacaine in adults is 2.7 hours and in neonates 8.1 hours. 
 Amide-type local anaesthetics such as bupivacaine are metabolized 
primarily in the liver via N-dealkylation and conjugation with glucuronic 
acid. The major metabolite of bupivacaine is 2, 6-pipecoloxylidine. 
Patients with hepatic disease, especially those with severe hepatic disease, 
may be more susceptible to the potential toxicities of the amide-type local 
anaesthetics.  
 The kidney is the main excretory organ for bupivacaine and its 
metabolites. Urinary excretion is affected by renal perfusion and factors 
affecting urinary pH. Only 5% of bupivacaine is excreted unchanged in 
the urine.  
Indications: Bupivacaine is indicated for local anaesthesia including 
infiltration, nerve block, epidural, and intrathecal anaesthesia and 
analgesia. 
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Contraindications: Bupivacaine is contraindicated for IV regional 
anaesthesia (IVRA) because of potential risk of tourniquet failure and 
systemic absorption of the drug and known allergy to bupivacaine. 
Adverse CNS effects: 
 CNS effects usually occur at lower blood plasma concentrations 
and additional cardiovascular effects present at higher concentrations, 
though cardiovascular collapse may also occur with low concentrations. 
 CNS excitation can manifest as nervousness, tingling around the 
mouth, tinnitus, tremor, dizziness, blurred vision, seizures followed by 
manifestation of CNS depression - drowsiness, loss of consciousness, 
respiratory depression and apnoea.                                                                                          
 Other central nervous system effects are nausea, vomiting, chills, 
and constriction of the pupils.  
 The incidence of convulsions associated with the use of local 
anaesthetics varies with the procedure used and the total dose 
administered. In a survey of studies of epidural anaesthesia, overt toxicity 
progressing to convulsions occurred in approximately 0.1% of local 
anaesthetic administrations 
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Neurologic 
 Neurologic effects following epidural or caudal anaesthesia may 
include -  spinal block of varying magnitude (including high or total 
spinal block); hypotension secondary to spinal block; urinary retention; 
fecal and urinary incontinence; loss of perineal sensation and sexual 
function; persistent anaesthesia, paresthesia, weakness, paralysis of the 
lower extremities and loss of sphincter control, all of which may have 
slow, incomplete or no recovery; headache; backache; septic meningitis; 
meningismus; slowing of labour; increased incidence of forceps delivery; 
or cranial nerve palsies due to traction on nerves from loss of 
cerebrospinal fluid.                                                                      
Cardiovascular effects :                                                                        
 Hypotension, bradycardia, decreased cardiac output, dose 
dependant depression of myocardium, arrhythmias, cardiac arrest  
Allergic:    
 Allergic type reactions are rare and may occur as a result of  
sensitivity to the local anaesthetic, to other formulation ingredients, such 
as the antimicrobial preservative methylparaben contained in multiple 
dose vials or sulfites in epinephrine-containing solutions.                                                      
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 These reactions are characterized by signs such as urticaria, 
pruritus, erythema, angioneurotic edema (including laryngeal edema), 
tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive 
sweating, elevated temperature, and possibly, anaphylactoid 
symptomatology (including severe hypotension).                                                                    
♦ Cross sensitivity among members of the amide-type local 
anaesthetic group has been reported.                                                                    
♦ The usefulness of screening for sensitivity has not been 
definitely established.  
Labour and Delivery. 
 Local anaesthetics rapidly cross the placenta, and when used for 
epidural, caudal or pudendal block anaesthesia, can cause varying degrees 
of maternal, foetal and neonatal toxicity. Local anaesthetics produce 
vasodilation by blocking sympathetic nerves and may produce maternal 
hypotension. Epidural, caudal, or pudendal anaesthesia may alter the 
forces of parturition through changes in uterine contractility or maternal 
expulsive efforts. Epidural anaesthesia has been reported to prolong the 
second stage of labour by removing the parturient's reflex urge to bear 
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down or by interfering with motor function. The use of obstetrical 
anaesthesia may increase the need for forceps assistance.  
 Nursing Mothers:   Bupivacaine has been reported to be excreted 
in human milk suggesting that the nursing infant could be theoretically 
exposed to a dose of the drug.  
FENTANYL: 
 Fentanyl is an opioid analgesic, first synthesized by Janssen 
Pharmaceutica (Belgium) in the late 1950s, with a potency 75 to 100 
times that of morphine. Fentanyl was introduced into medical practice in 
the 1960s.  The chemical name of fentanyl is N-phenyl-N-(1-phenethyl-
4-piperidinyl) propanamide. 
 Molecular mass                 336.471 g/mol 
 Melting point                     87.5 degrees Celsius 
 
THERAPEUTIC CONSIDERATIONS 
Pregnancy                   Category C 
Routes                 Intravenous, intramuscular, transdermal,   
         buccal, sublingual, oral, intrathecal,   
         epidural. 
 31
       The LD50 in humans, by intravenous injection, is 0.2-1 milligrams. 
Analogues 
• Alfentanil, an ultra-short acting (5–10 minutes) analgesic,  
• Sufentanil , a potent analgesic (5 to 10 times more potent than 
fentanyl) .  
• Remifentanil , currently the shortest acting opioid, has the benefit of 
rapid offset, even after prolonged infusions.  
• Carfentanil , an analogue of fentanyl with an analgesic potency 10,000 
times that of morphine and is used in veterinary practice to immobilize 
certain large animals.  
Mechanism of Action 
 Binds with stereo specific receptors – mu 2 receptor agonist at 
many sites within the CNS and other tissues. It prevents the release of 
endogenous opioids- beta endorphin and increases pain threshold, alters 
pain reception, inhibits ascending pain pathways. 
PHARMACOKINETIC DATA 
Protein binding                 80-85% 
Lipid solubility                  High 
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Distribution                       Highly lipophilic, redistributes into muscle  
     and fat  
Metabolism                       Hepatic, CYP3A4 
Onset                                 5 to 9 minutes 
Duration                              I.M: 1-2 hours, I.V: 0.5-1 hour,   
       Transmucosal: Related to blood level. 
Half life                               3 to 12 hours (average 7 hours) 
Excretion                             Urine (primarily as metabolites, less than  
                 8% as unchanged drug)  
 Metabolism: Hepatic, primarily via CYP3A4. Extensively 
metabolized by N-dealkylation, hydroxylation and amide hydrolysis to 
inactive metabolites including norfentanyl and despropionyl norfentanyl 
and excreted via bile and urine.  Fentanyl is significantly more lipid-
soluble, compared to morphine and, relative to morphine, has a more 
rapid onset of action .It is also a weak base and at physiological pH only 
about 10% of molecules are un-ionized. Clearance of about 10-20 
ml/kg/minute is consistent with a primary hepatic mechanism.  Fentanyl’s 
short duration of action following bolus administration is explained by 
rapid redistribution from brain to other compartments such as skeletal 
muscle and fat. If, however, fentanyl is administered by continuous IV 
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infusion or multiple IV dosing, other non- CNS compartments will get 
saturated and the remaining CNS fentanyl will contribute to postoperative 
ventilatory depression.  
Therapeutic use 
 Fentanyl is extensively used for anaesthesia and analgesia, most 
often in the operating room and intensive care unit for the purpose of, 
premedication—1-2mcg/kg IM 30-60 minutes prior to induction, 
analgesia—1-4mcg/kg IV, to blunt circulatory responses – 5-10mcg/kg 
IV, large doses of fentanyl—50-100mcg/kg IV to produce surgical 
anaesthesia, narcotic supplementation for general anaesthesia and regional 
anaesthesia, obstetric analgesia and neuroleptanalgesia with droperidol.       
 Fentanyl transdermal patch –50-100mcg/hour used in chronic pain 
management. Fentanyl patches work by releasing fentanyl into body fats, 
which then slowly release the drug into the blood stream over 72 hours, 
allowing for long lasting relief from pain 
 Fentanyl lozenges are solid formulation of fentanyl citrate on a 
stick in the form of a lollipop that dissolves slowly in the mouth for 
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transmucosal absorption. These lozenges are intended for opioid-tolerant 
individuals and are effective in treating breakthrough pain.   
 The development of small fentanyl buccal pellets may be much 
more practical. These are effervescent tablets placed in the cheek and are 
absorbed through the buccal mucosa. One advantage of such tablets is 
claimed to be quicker absorption into the bloodstream at lower dosage 
levels.                                                                                                                
 Fentanyl is frequently given intrathecally as part of spinal 
anaesthesia and analgesia or epidurally for epidural anaesthesia and 
analgesia. It is also used as a sedative. 
Adverse effects 
 Like other lipid soluble drugs, the pharmacodynamics of fentanyl 
are poorly understood. Fentanyl has a therapeutic index of 270. 
 Cardiovascular: Hypotension, bradycardia, cardiac arrhythmia, 
oedema, orthostatic hypotension, hypertension, syncope.  
 Respiratory: Respiratory depression, apnea, bronchitis, dyspnea, 
hemoptysis, pharyngitis, rhinitis, sinusitis, upper respiratory infection.                          
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The precise reason for sudden respiratory depression is unclear, but there 
are several hypotheses: 
• Saturation of the body fat compartment in patients with rapid and 
profound body fat loss (patients with cancer, cardiac or infection-
induced cachexia can lose 80% of their body fat).  
• Early carbon dioxide retention causing cutaneous vasodilatation 
(releasing more fentanyl), together with acidosis which reduces protein 
binding of fentanyl (releasing yet more fentanyl).  
• Reduced sedation, losing a useful early warning sign of opioid 
toxicity, and resulting in levels closer to respiratory depressant levels.  
 Central nervous system: CNS depression, confusion, drowsiness, 
sedation, abnormal dreams, abnormal thinking, agitation, amnesia, 
dizziness, euphoria, fatigue, fever, hallucinations, headache, insomnia, 
nervousness, paranoid reaction.  
 Gastrointestinal: Nausea, vomiting, constipation, xerostomia, 
abdominal pain, anorexia, biliary tract spasm, diarrhoea, dyspepsia, 
flatulence.  
 36
 Neuromuscular & skeletal: Chest wall rigidity (high dose I.V.), 
weakness, abnormal coordination, abnormal gait, back pain, paresthesia, 
rigors, tremor.  
Miscellaneous:  Miosis Diaphoresis, Hiccups, flu-like syndrome, speech 
disorder. 
Dermatologic: Erythema, papules, pruritus, rash, urticaria 
Local: Application site reaction  
Over dosage/Toxicology 
 Symptoms of overdose include CNS depression, respiratory 
depression, and miosis. Treatment is supportive. Naloxone, 2 mg I.V. 
with repeat administration as necessary up to a total of 10 mg, can also be 
used to reverse toxic effects of the opiate. Patients who experience 
adverse reactions during use of transdermal fentanyl should be monitored 
for at least 24 hours after removal of the patch. 
Drug Interactions 
Substrate of CYP3A4 (major); Inhibits CYP3A4 (weak)  
 CNS depressants: Increased sedation with CNS depressants, 
phenothiazines  
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 CYP3A4 inhibitors: May increase the levels/effects of fentanyl. 
Potentially fatal respiratory depression may occur when a potent inhibitor 
is used in a patient receiving chronic fentanyl (eg. transdermal). Example 
of inhibitors include azole antifungals, ciprofloxacin, clarithromycin, 
diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, 
nicardipine, propofol, protease inhibitors, quinidine, and verapamil.  
 MAO inhibitors: Not recommended to use fentanyl within 14 days. 
Severe and unpredictable potentiation by MAO inhibitors has been 
reported with opioid analgesics.  
Pregnancy Implications: Category C/D. Fentanyl crosses the placenta 
and has been used safely during labour. Chronic use during pregnancy has 
shown detectable serum levels in the newborn with mild opioid 
withdrawal. 
Lactation : Enters breast milk/not recommended (American 
Academy of Paediatrics rates "compatible"). 
Contraindications: Hypersensitivity to fentanyl or any component of the 
formulation. severe respiratory disease or depression. 
 38
EFFECT OF COMBINATION OF LOW 
CONCENTRATIONS OF BUPIVACAINE WITH OPIOID: 
 Low concentrations of local anaesthetics placed neuraxially 
blocking conduction by A delta fibres and also inhibiting sympathetic 
nerve transmission. Opiates administered neuraxially produce a selective 
block of nociceptive pathways, blocking pain transmission via the C 
fibres more readily than A delta fibres. Combination of low concentration 
of local anaesthetics with low dose opioids eliminate pain via a combined 
and possible synergistic mechanism by working at two distinct sites- local 
anaesthetic at the nerve axon and the opioid at the spinal level. 
1) Faster in onset 
2) Intense and long lasting sustained analgesia 
3) Provides excellent analgesia during first stage of labour 
without affecting uterine contractility 
4) Tendency to decrease the duration of active phase of first 
stage of labour 
5) Addition of opioids significantly decreases the amount of 
opioids required 
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REVIEW OF LITERATURE 
1. CSE analgesia for labour is usually achieved using a short-acting 
lipid soluble narcotic such as fentanyl or sufentanil.  Although 
pruritus is associated with lipid soluble opioids, it is usually mild 
and short lived and does not generally need to be treated. Advances 
in labour analgesia David J. Birnbach, MD Canadian Journal of 
Anaesthesia 51:R12 (2004) 
2. Of all the possible methods of pain relief which can be used in 
labour, neuraxial blockade (epidural, spinal, CSE, continuous 
spinal) provides the most effective and least depressant analgesia. 
The combination of epidural and spinal anaesthesia into one 
technique, termed "CSE" provides the advantages of a spinal (speed 
of onset, lack of motor block) with the additional flexibility of 
renewal with an epidural catheter .Advances in labour analgesia 
David J. Birnbach, MD Canadian Journal of Anaesthesia 51:R12 
(2004) 
3. CSE provides better pain relief in the early stages after insertion. 
Comparative Obstetric Mobile Epidural Trial (COMET) Study 
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Group. Randomized controlled trial comparing traditional with two 
"mobile" epidural techniques. Anesthesiology 2002; 97: 1567–75. 
4. A review of the complications associated with CSE has concluded 
that CSE is as safe a technique as a conventional epidural technique 
and is associated with greater patient satisfaction.  Norris MC, 
Grieco WM, Borkowski M, et al. Complications of labour 
analgesia: epidural versus combined spinal-epidural techniques. 
Anesth Analg 1995; 79: 529–37. 
5. We conclude that intrathecal bupivacaine 1.25 mg with fentanyl 25 
micrograms provided analgesia of similar onset and quality 
compared with bupivacaine 2.5 mg and fentanyl 25 micrograms. 
Although the duration of analgesia was shorter, the incidences of 
motor block and hypotension were less with the smaller dose. Br J 
Anaesth. 1999 Dec;83(6):868-71. Combined spinal-epidural 
analgesia in labour: comparison of two doses of intrathecal 
bupivacaine with fentanyl. Lee BB, Ngan Kee WD, Hung VY, 
Wong EL. Department of Anaesthesia and Intensive Care, Chinese 
University of Hong Kong, Prince of Wales Hospital, Shatin, China.                   
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6. The combined spinal epidural analgesia will only result in 
significant falls in systolic blood pressure within 30 minutes of the 
spinal injection. No further important changes in blood pressure 
occur when mobilising or with epidural top-ups. The combined 
spinal epidural analgesia may modify the normal compensatory 
mechanisms of blood pressure control, but does not cause 
significant maternal hypotension once the spinal injection has been 
given: Br J Obstet Gynaecol. 1995 Mar;102(3):192-7. Blood 
pressure changes during labour and whilst ambulating with 
combined spinal epidural analgesia. Shennan A, Cooke V, Lloyd-
Jones F, Morgan B, de Swiet M. Queen Charlotte's and Chelsea 
Hospital, London. 
7. R. Fernando et al (1997) have used low dose combination of 
bupivacaine – fentanyl combination for labour analgesia, in the 
form of combined spinal epidural analgesia. He concluded that the 
combination of drugs resulted in smaller levels of  drug in both 
mother and neonate and is of little clinical significance in contrast 
to intramuscular pethidine which has longer acting neonatal effects. 
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8. David J Birnbach in the New England Journal of  Medicine (1997) 
reported that combined spinal epidural analgesia combining the 
intrathecal administration of an opioid drug through a fine spinal 
needle with the subsequent epidural administration of low dose 
mixtures of local anaesthetic and opioid drugs through a catheter 
resulted in faster onset analgesia, decreased motor block(thus 
allowing them to walk) and a greater sense of control.   
9. Curelaru “The advantage of CSEA is the possibility of obtaining a 
high quality conduction anaesthesia, unlimited in time …”. Long 
duration sub-arachnoid anaesthesia with continuous epidural block. 
Prktische Anasthesie Wider belelung and Intensivtherapie 
1979;14:71-78.  
10. Anaesthesiologists were more inclined to using CSE than EA for 
multiparous parturients in a more painful advanced stage of labour. 
Patient satisfaction was higher for CSE. A T Sia and colleagues, 
Neuraxial Block for Labour Analgesia, Singapore Med J 2003 Vol 
44 (9) : 464-470. 
11. Combined spinal – epidural analgesia has the advantages of faster 
onset of analgesia, decreased motor block and a greater sense of 
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control. The New England Journal of Medicine, Vol 337:1764-
1766. 
12. Epidural analgesia with a low concentration of local anaesthetic 
and opioid mixture takes longer to produce complete analgesia, it is 
a satisfactory alternative to CSE. David L. Hepner, MD and 
collogues.  
13. Labor progress and outcome are similar among women receiving 
either combined spinal-epidural or epidural analgesia and not 
associated with an increased frequency of anaesthetic 
complications. Mark C Norris MD and colleagues. Combined 
Spinal – Epidural versus Epidural Labor Analgesia Anaesthesiology 
2000;95:913-20. 
14. Opioids administered in combination with local anaesthetics have a 
synergistic effect with various local anaesthetic agents, reducing the 
ED. However is associated with an increased incidence of pruritus. 
Marc Van De Velde, European Society of Anaesthesiologists, 
Drug Combinations inRegional Analgesia During Labou, Sunday 
June6,2004. 
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15. Any  epidural has the potential to be a “walking epidural”. As 
motor block will imede the woman’s ability to ambulate, more 
dilure solutions of local anaesthetic are used and combined with an 
opioid such as fentanyl. Obstetric Guideline Pain Management 
During Labour, British Columbia Reproductive Care Program. 
16. the combination of spinal opioids with subsequent epidural 
analgesia has been suggested to provide the best of both techniques: 
rapid onset of analgesia with a minimal drug dose, followed by 
great flexibility of continuous analgesia. Anesthesiology Vol 91(1); 
July 1999 : pp299-302. 
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MATERIALS AND METHODS 
The study was conducted at Government Rajaji Hospital, Madurai 
attached to Madurai Medical College, Madurai. The study was conducted 
between September 2005 and June 2007. 
  A pilot study was conducted on a small group of patients before the 
actual study in order to assess the feasibility of the study, to understand 
the needs and demands of out population to be studied, to assess the drug 
requirements of bupivacaine and fentanyl in our population. 
 Based on the pilot study, the concentration of bupivacaine and the 
dose of fentanyl was decided and the main study was proceeded. 
 The study involved 75 parturients in active labour with term 
gestation, belonging to ASA I class with singleton pregnancies with 
vertex presentation and no cephalo-pelvic disproportion. 
Exclusion Criteria : Parturient with cardiac or respiratory diseases, 
spinal deformities, local skin sepsis, coagulopathies, parturients who have 
received systemic opioids early in labour, parturient refusal, pre-
eclampsia, anaemia complicating pregnancy, multiple gestation, breech 
presentation, previous caesarean section and known H/O allergy to local 
anaesthetics and / or fentanyl.  
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 A written informed consent was obtained from both the study group 
after explaining the procedure in detail.  
 75 cases were selected at random and grouped into 25 in the 
combined spinal epidural analgesia group (CSEA), 25 in the epidural 
analgesia group (EA) and 25 in the control group Each group in turn 
included 12 primigravida and 13 multigravidae. The above sub-grouping 
was done as the primi and multigravidae behave entirely different in the 
labour process and progress. All the study groups were well matched in 
terms of age, height, weight, parity and labour characteristics. 
 The following resuscitative equipment were kept ready before the 
start of the procedure to treat complications if any that could occur - 
anaesthesia machine with full oxygen supply, airways of different sizes, 
laryngoscope with appropriate size blades, endotracheal tubes of 
appropriate sizes, laryngeal mask airways of appropriate sizes, McCoy 
laryngoscope blade and bougie, functioning suctioning apparatus, Inj. 
Thiopentone or benzodiazipine for the treatment of possible convulsions. 
Inj. Ephedrine for treatment of hypotension, Inj. Atropine for treatment of 
bradycardia, Inj. Naloxone for the treatment of opioid induced respiratory 
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depression and other intractable side effects and emergency drug tray with 
all essential drugs. 
For initiating epidural block, the following were kept ready:- Draping 
towels and sponge holding forceps, sterile gauze pieces in kidney tray, 
bowls with antiseptic solution, 18 G Tuohy needle with 20 G portex 
epidural catheter with filter and loss of resistance syringe for single use, 2 
ml syringe with 24 G needle for local anaesthetic infiltration, 5 ml and 
10ml syringe with needles to draw up fentanyl and bupivacaine 
respectively, Inj. Bupivacaine – 0.25% preservative free vial, Inj. 
Lignocaine – 2% vial, Inj. Fentanyl ampoules, distilled water, saline and 
metal files to open ampoules, delivery tray, baby resuscitation tray and 
waterproof adhesive plasters. 
 
 For initiating combined spinal epidural block in addition to above 
27 G Quincke needle was kept ready. 
 
Technique of Epidural Analgesia  
Following parturient selection a through evaluation of her medical 
and obstetric condition was done. Physical examination included 
examination of pulse rate, blood pressure, respiratory rate, SpO2, 
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cardiovascular, central nervous system and respiratory system 
examination. Back of the parturient was examined to rule out local skin 
sepsis, spina bifida or kypho-scoliosis. Parturients height and weight were 
recorded. Description of the 10 point linear visual analogue scale (VAS) 
was given. Obstetrician recorded the nature of the uterine contraction, 
cervical dilatation, station of the Foetal head and the foetal heart rate. 
An intravenous line was set up and 500ml of lactated Ringers 
solution was started. Pulse oximeter and non invasive blood pressure 
monitoring were used in order to note the arterial oxygen saturation, pulse 
rate and blood pressure. 
Parturient was placed in lateral position on a horizontal table. 
Under strict aseptic precautions L2-3/L3-4 epidural space was identified 
by loss of resistance to saline technique with 18 G Tuohy epidural needle. 
Epidural catheter was inserted through the needle. Test dosing was 
done using 3ml of 1.5% lignocaine with 1:2,00,000 adrenaline to rule out 
intravascular and intrathecal placement of catheter and fixed by sterile 
dressing and water proof adhesive plasters. 
The parturients were positioned supine with left uterine 
displacement. After negative aspiration for blood and cerebrospinal fluid, 
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10ml of 0.125% preservative free bupivacaine with 2 µcg/ml of Inj. 
Fentanyl was given initially. 
Top ups of above dosage were given at the end of every one hour 
since previous dosage. The top up volume was reduced to 6-8ml if there 
was significant hypotension, bradycardia or sedation. 
Technique of combined spinal epidural analgesia using double 
needle, double space / interspace method: 
Pre procedure preparation was same as for epidural group. 
Under strict aseptic precautions sub-arachanoid space is entered at 
L3-4/L2-3 interspace using 27 G Quincke spinal needle. 
25 µcg of Inj. Fentanyl with 0.5ml of preservative free 0.25% 
bupivacaine was injected intrathecally 
- Subsequent identification of the epidural space one space above 
spinal injection, catheter placement and fixation were proceeded 
with, as in epidural group. 
- First epidural dose of 10ml of 0.125% preservative free 
bupivacaine with 2µcg of Inj. Fentanyl was given 45 minutes 
after intrathecal fentanyl administration. 
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- Subsequent top ups of same or reduced dosage based on heart 
rate, blood pressure  and sedation are administered at the end of 
every hour since previous dosing. 
Both the Groups  
- All epidural top ups were given in 2-3ml increments at 1-2 
minute intervals (maximum of 10ml/hr). 
- Any breakthrough pain (VAS >4) managed with 6-8ml of same 
drug mixture. 
- Depending upon parturient need the obstetrician was allowed to 
use artificial rupture of membranes, Inj. Oxytocin for 
acceleration etc. 
- During the second stage of labour, the parturients were 
encouraged to bear down. 
- Episiotomy and episiotomy repair were preceeded by local 
anaesthetic infiltration since above combination of low 
concentration bupivacaine and fentanyl does not provide 
surgical plane of analgesia.              
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 Monitoring  
1. Blood pressure every 2 minutes for the first 15 minutes after 
giving loading dose and then every 10 minutes. 
2. Continuous maternal and foetal heart rate and maternal SpO2 
monitoring  
3. Continues verbal communication with the parturient in order to 
assess pain relief. 
4. The time of onset of analgesia was noted. Parturients were asked 
to mark a point on the 10 point linear visual analogue scale 
(VAS) every 15 minutes to evaluate the adequacy of pain relief 
which was graded by Elbaz 1984. 
  If VAS score was >4, it was considered to be breakthrough 
pain and additional epidural top up dose was given as mentioned 
earlier. 
5.  The level of sensory analgesia and intensity of motor blockade 
were assessed at half hourly intervals. 
Motor block : Bromage scale (BONICA – 1995) 
0 - No block (10%) - Full flexion of knees and feet possible  
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1  - Partial (33%) - Just able to flex knees, still full flexion 
of feet possible.   
     2 - Almost complete (66%) – Unable to flex knees, still full  
    flexion of feet possible 
     3 - Complete  - Unable to move legs or feet  
6. The total dose of bupivacaine and fentanyl administered were noted in 
each group. 
7. Complications : Pruritis, sedation, urinary retention, nausea, vomiting, 
shivering, headache, backache, hypotension, bradycardia and respiratory 
depression were noted.      
Sedation score:          Grading of Nausea: 
0 - Fully awake and oriented      0 - None  
1 - Normal sleep       1 - Mild  
2 - Drowsy, arousable on touch or call   2 - Moderate  
3 - Drowsy, arousable on painful stimulus   3 - Severe  
4 - Somnolent, difficult to arouse  
The following obstetric parameters were noted  
1. Duration and frequency of uterine contractions recorded every 15 
minutes. 
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2. Rate of cervical dilatation and progress of labour. 
3. Duration of first, second and third stages of labour. 
4. Mode of delivery.  
5. Apgar score.   
 Any sign of maternal or foetal distress were taken as an indication 
for early termination of labour. 
 As the baby is born, APGAR score as noted and neonatal outcome 
was recorded by the paediatrician.    
 
Statistical Tools : 
 The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002). 
Using this software, frequencies, percentage, mean, standard 
deviation, x2 and  'p' values were calculated. A 'p' value less than 0.05 is 
taken to denote significant relationship.  
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OBSERVATION AND RESULTS 
AGE DISTRIBUTION: 
Primi  
 Analyzing the age of the parturient in the combined spinal epidural 
group primi group was in the range of 19 to 26 years with a mean age 
group of  22.58 (2.19) years. In the epidural group primi group was in the 
range of 18 to 26 years with a mean age group of 22.08 (2.39) years. The 
control group primi age was in the range of 18 yo 30 years with mean 
score of 23.16 (3.30) years. 
Multi  
 In the CSEA group the multi group was in the range of 18 to 32 
years with a mean age group of 25.15 (3.8) years. In the EA group multi 
was in the range of 20 to 31 years with a mean age group of 25.85 (2.85) 
years. Both the CSEA and the EA group were comparable with respect to 
age. In the control group multi range fell between 19 to 35 tears with an 
average mean of 25.72 (3.38) years. The control group was comparable to 
both the study groups with respect to age and the difference was 
statistically insignificant. 
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HEIGHT, WEIGHT CHARACTERISTICS: 
Primi   
 In the CSEA group the mean height in the primi group was 152.67 
(5.91) cm and the mean weight was 55.75 (10.91) kgs. In the epidural 
group the mean height in the primi group was 154.33 (5.42) cm and the 
mean weight was 56.33 (10.85) kgs. In the control group the mean height 
in the primi group was 151.8(6.6) cm and the mean weight was 
55.52(4.37) kgs.  
Multi  
 In the CSEA group among multi mean height and weight were 
153.38 (6.09) cm and 61.69 (7.17) kgs respectively whereas in the EA 
group it was 154.69 (4.4) cm and 62.15 (7.85) kgs respectively and in the 
control group it was 153.04(4.64) cm and 54.68(6.13) kgs respectively.  
 Both the CSEA and EA groups were comparable with respect to 
height and weight. The study and control groups were comparable with 
respect to height and weight and the difference was statistically 
insignificant. 
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RATE OF CERVICAL DILATATION: 
 
Primi:  
 The mean rate of cervical dilatation per hour in the primigravidae in 
CSEA group was 3.42(0.38) cm and in the EA group it was 4.22(0.52) 
cm. The mean rate of cervical dilatation per hour in the control group 
among primigravidae in was 1.63(1.04) cm. 
 
Multi:  
 
 The mean rate of cervical dilatation per hour in the multiigravidae 
in CSEA group was5.97 (0.58) cm and in the EA group it was 6.03(0.62) 
cm. The mean rate of cervical dilatation per hour in the control group 
among the multi it was 2.00(1.01) cm.  
 The mean rate of cervical dilatation was comparable between 
CSEA and EA groups.  
 The difference in the mean rate of cervical dilatation between the 
control group and CSEA group was statistically significant and the 
difference in the mean rate of cervical dilatation between the control 
group and EA group was also statistically significant.  
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AMOUNT OF DRUGS USED: 
Bupivacaine  
Primi  
 
      The amount of bupivacaine (in milligrams) used in CSEA group was 
on an average 31.83(15.76) and in the EA group it was on an average 
32.92(6.11). 
Multi  
 The amount of bupivacaine (in milligrams) used in CSEA group on 
an average was 17.86(6.54) and in the EA group it was 22.5(6.85). 
 The difference was not significant among both primi and multi. 
Fentanyl  
Primi  
 The amount of fentanyl (in micrograms) used in CSEA group was 
on an average 74.3(25.25) and in the EA group it was 52.67(9.77). 
Multi  
 The amount of fentanyl (in micrograms) used in CSEA group was 
on an average 50.23(8.85) and in the EA group it was 36.0(10.95). 
 The difference was significant among both primi and multi.  
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TOTAL NO OF TOP UPS GIVEN: 
Primi  
 
 The average number of top ups required in primi was 2.5(1.24) in 
CSEA group and 2.83(0.58) in EA group.  
Multi  
 The average number of top ups required in multi was 1.38(0.51) in 
CSEA group and 1.85(0.55) in EA group.  
 The difference was significant among both primi and multi. 
ONSET OF PAIN RELIEF: 
CSEA  
 Onset of analgesia in the CSEA group was within 1 to 2 minutes in 
both the primi and multi gravidae with a mean of 1.71(0.33) minutes in 
primi and 1.38(0.36) minutes in multi.   
EA 
 Onset of analgesia in the EA group was within 3 to 7 minutes in 
both the primi and multi gravidae with a mean of 5.25(1.36) minutes in 
primi and 4.46(1.05) minutes in multi.                                                                                    
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 Time to get the painless uterine contraction was noted and was 
taken as the onset time. There was a significant difference in the onset 
times between the two study groups with the CSEA group having rapidity 
of analgesic onset as early as 1 minute post block. 
QUALITY OF PAIN RELIEF: 
Primi  
 The mean VAS score in primi of CSEA group was 1.4 (0.73) and in 
the EA group was 2.54(0.97).  
Multi  
 The mean VAS score in multigravidae of CSEA group was 
0.51(0.24) and in the EA group was 1.27(0.6). 
 On analysis of the VAS scores between the two groups there is a 
statistically significant difference both among primi and multi gravidae. 
Of greater significance is the immediate post block scores which average 
0.31(0.18) in primi and 0.15(0.15) in multi of the CSEA group. 
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GRADING: 
CSEA 
   
 Pain relief was excellent in 84%, good in 12 % and satisfactory in 
4% of parturients who received CSEA.  
EA 
 Pain relief was excellent in 52%, good in 32% and satisfactory in 
16% of parturients who received EA. 
 
BREAKTHROUGH PAIN:                                                                                                  
 Breakthrough pain occurred in 4% of parturients who received 
CSEA and in 16% of parturients who received EA. The difference was 
significant statistically (p<0.5). 
SENSORY LEVEL: 
 The sensory level obtained was adequate and between T6 to T10 in 
both the groups. 
 
 
 
 
 61
DURATION OF LABOUR: 
DURATION OF FIRST STAGE (ACTIVE PHASE) OF LABOUR:  
Primi: The average duration of the first stage of labour in the primi 
(CSEA) group was 122.92 (45.8) minutes. The average duration of the 
first stage of labour in the primi (EA) group was 99.6 (15.2) minutes. The 
difference was statistically insignificant. 
 The average duration of the first stage of labour in the primi 
(CSEA) group was 122.92 (45.8) minutes. The average duration of the 
first stage of labour in the primi (Control) group was 201.47(57.78) 
minutes. The difference was statistically significant. 
 The average duration of the first stage of labour in the primi (EA) 
group was 99.6 (15.2) minutes. The average duration of the first stage of 
labour in the primi (Control) group was 201.47(57.78) minutes. The 
difference was statistically significant. 
Multi: The average duration of the first stage of labour in the multi 
(CSEA) group was 70.38 (23.98) minutes. The average duration of the 
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first stage of labour in the multi (EA) group was 69.63 (25.84) minutes. 
The difference was statistically insignificant. 
 The average duration of the first stage of labour in the multi 
(CSEA) group was 70.38 (23.98) minutes. The average duration of the 
first stage of labour in the multi (Control) group was 145 (38.83) minutes. 
The difference was statistically significant. 
 The average duration of the first stage of labour in the multi (EA) 
group was 69.63 (25.84) minutes. The average duration of the first stage 
of labour in the multi (Control) group was 145 (38.83) minutes. The 
difference was statistically significant. 
DURATION OF SECOND STAGE OF LABOUR:  
Primi: The average duration of the second stage of labour in CSEA group 
was 51.5(24.97) minutes. The average duration of the second stage of 
labour in EA group was 46.67 (11.02) minutes. The difference was 
statistically insignificant.  
 The average duration of the second stage of labour in CSEA group 
was 51.5 (24.97) minutes. The average duration of the second stage of 
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labour in Control group was 37.85 (20.9) minutes. The difference was 
statistically insignificant.  
 The average duration of the second stage of labour in EA group 
was 46.67(11.02) minutes. The average duration of the second stage of 
labour in control group was 37.85 (20.9) minutes. The difference was 
statistically insignificant.  
Multi  
 The average duration of the second stage of labour in the CSEA 
group was 21.46(5.29) minutes. The average duration of the second stage 
of labour in the EA group was 23.46(8.06) minutes. The difference was 
statistically insignificant.  
 The average duration of the second stage of labour in the CSEA 
group was 21.46 (5.29) minutes. The average duration of the second stage 
of labour in the Control group was 20.76 (12.8) minutes. The difference 
was statistically insignificant.  
 The average duration of the second stage of labour in the EA group 
was 23.46(8.06) minutes. The average duration of the second stage of 
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labour in the Control group was 20.76(12.8) minutes. The difference was 
statistically insignificant.  
DURATION OF THIRD STAGE OF LABOUR: 
 The average duration of the third stage of labour was comparable 
among primi and multi of CSEA, EA and control groups. There was no 
statistically significant difference.   
TOTAL DURATION OF LABOUR: 
Primi : The mean total duration of labour in the CSEA group was 
180.67(67.53) minutes. The mean total duration of labour in the EA group 
was 152.33 (26.38) minutes. The difference was statistically insignificant. 
The mean total duration of labour in the control group was 246.92 (24.25) 
minutes. The difference was statistically significant between the study and 
control groups. 
Multi  
 The mean total duration of labour in the CSEA group was 96.46 
(28.99) minutes. The mean total duration of labour in the EA group was 
95.92 (33.32) minutes. The difference was statistically insignificant. The 
mean total duration of labour in the control group was 171.53(15.44) 
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minutes. The difference was statistically significant between the study and 
control group. The mean total duration of labour in the multi (EA) 
group was 95.92(33.32) minutes. The mean total duration of labour in the 
multi (Control) group was 171.53(15.44) minutes. The difference was 
statistically insignificant. The difference was statistically significant. 
MODE OF DELIVERY: 
Primi:  50% of the primi in the CSEA group had natural labour and 50% 
of the primi in EA group also had labour naturale. The results were 
comparable between the two study groups. 41.7% had instrumental 
delivery in CSEA group and 50% had instrumental delivery in the EA 
group. One primi gravida in the CSEA had caesarean delivery and none in 
EA group. The results were comparable and not statistically significant.                          
84% in the control group had labour naturale which was statistically 
significant when compared with those in CSEA and EA groups. Only 
16.7% had instrumental delivery in the control group which again was 
statistically significant when compared to those in CSEA and EA groups. 
None had caesarean delivery in the control group which was comparable 
to those in the CSEA and EA groups.  
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Multi: 100 % of the multi in the CSEA group had natural labour and 
92.3% of the multi in EA group also had labour naturale. The results were 
comparable between the two study groups. None had instrumental 
delivery in CSEA group and 7.7% had instrumental delivery in the EA 
group.  None had caesarean delivery in either CSEA or EA group. The 
results were comparable and not statistically significant.                           
92% in the control group had labour naturale which was statistically not 
significant when compared with those in CSEA and EA groups. Only 8% 
had instrumental delivery in the control group which again was 
statistically not significant when compared to those in CSEA and EA 
groups. None had caesarean delivery in the control group which was 
comparable to those in the CSEA and EA groups.  
INDICATIONS FOR ASSISSTED DELIVERY: 
 Assisted deliveries include both forceps and lower segment 
caesarean section deliveries. Among the primigravidae assisted delivery 
was required by 50% in the CSEA group and 50% in the EA group. 
Among the multigravidae assisted delivery was required by none in the 
CSEA group and by 7.7% in the EA group.  
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 In the control group 8.3% of primigravidae required assisted 
delivery and 7.69% of multigravidae required assisted delivery.    
 
APGAR SCORE: 
 Foetal wellbeing was assessed using the APGAR scoring done at 1 
minute and 5 minutes from the time since birth. The mean APGAR in the 
study (CSEA, EA) and control group among both primi and multi were 
similar.  
COMPLICATIONS: 
 Pruritis was the most common complication occurring during 
CSEA (96%) followed by sedation (84%). In the EA group 32% had 
pruritis and 20% had sedation. The differences were statistically 
significant. Nausea and vomiting occurred in 16% of CSEA group and in 
12% of EA group. The difference was statistically insignificant. Shivering 
occurred in 24% of CSEA group, 20% of EA group and 4% of control 
group. The difference was statistically insignificant. Headache occurred in 
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8% of CSEA group and in 4% of EA group. The difference was 
statistically insignificant. 
 Backache occurred in 4% of CSEA and in 8% of control group. 
 Urinary retention occurred in 4% each of CSEA and EA groups.                           
 Motor blockade occurred only in one parturient (4%) in the EA 
group which was of grade-1(modified bromage scale).             
 Hypotension occurred in 12% of CSEA and in 4% of EA group.                                  
 Incidence of respiratory depression associated with neuraxial 
opioids is dose dependent and typically ranges from 0.1 to 0.9% .There 
was no instance of respiratory depression in either of the study groups.        
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DISCUSSION 
 Pain perception by the parturient is a dynamic process that involves 
both the peripheral and central mechanisms and as reported on the McGill 
pain questionnaire, is one of the most intense pain that a woman can 
experience. 
 Regional techniques used in obstetrics provide optimal analgesia 
with minimal depressant effects on the mother and fetus while allowing 
the parturient to be awake and be able to participate in labour and 
delivery. 
 In CSEA intrathecal opioids and local anaesthetics are injected and 
an epidural catheter is left in place. The principle advantages of low dose 
CSEA in labour are speed of onset, selective neural blockade, fine tuning 
of block with minimal sympathetic, motor, sensory, proprioceptive block 
which allows walking, voiding, bearing down, flexibility – block can be 
easily converted to anaesthesia for operative or assisted delivery, drug 
dose requirement is reduced, predictable, reliable- less incidence of 
failures or patchy block compared to epidural alone and improved 
maternal satisfaction. 
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 Bupivacaine is the most widely used long acting amide local 
anaesthetic drug used in obstetric analgesia. It is effective in 0.125% or 
greater (0.0625%) dilution when combined with opioids. It produces high 
quality analgesia with minimal motor block. It has low potential for 
cumulative toxicity and produces differential blockade. 
 Addition of fentanyl to bupivacaine allows the use of reduced 
concentrations of bupivacaine without compromising analgesia and 
achieves a reduction in the motor block. It is this reduction in the motor 
block which is a major driving force behind the use of neuraxial opioids. 
 All parturients in both the study groups and in the control group 
went in for spontaneous labour and were included in the study from the 
active phase of labour. Labour was augmented either with artificial 
rupture of membranes or oxytocin infusion as per the needs of the 
parturient. 
AGE 
 Analyzing the age of the parturient both the primi and multi in the 
CSEA, EA and control group were comparable.  
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PARITY  
 In the multigravidae the distribution of parity was second gravidae- 
10, third gravidae- 2 and fourth gravidae- 1 in both CSEA and EA groups 
and in the control group it was second gravidae- 9, third gravidae- 3and 
fourth gravidae- 1. The study and control groups were comparable. 
 
HEIGHT AND WEIGHT DISTRIBUTION: 
 Both primi and multigravidae in the CSEA, EA and  control  group 
were comparable with respect to height and weight. 
ANALGESIA: 
CSEA: Onset of analgesia in the CSEA group was within 1 to 2 minutes 
in both the primi and multi gravidae with a mean of 1.71(0.33) minutes in 
primi and 1.38(0.36) minutes in multi.   
EA: Onset of analgesia in the EA group was within 3 to 7 minutes in both 
the primi and multi gravidae with a mean of 5.25(1.36) minutes in primi 
and 4.46(1.05) minutes in multi. 
VAS Score on analysis: Of the VAS scores between the two groups there 
is a statistically significant difference both among primi and multi 
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gravidae. The mean VAS score in primi of CSEA group was 1.4 (0.73) 
and in the EA group was 2.54(0.97). The mean VAS score in 
multigravidae of CSEA group was 0.51(0.24) and in the EA group was 
1.27(0.6).                                                                                                                             
 Of greater significance is the immediate post block scores which 
average 0.31(0.18) in primi and 0.15(0.15) in multi of the CSEA group. 
This is due to the effect of intrathecal fentanyl and it also contributes to 
the enhanced analgesic quality of subsequent epidural top ups due to its 
effects known to last for 2 to 3 hours. 
 Grading: Pain relief was excellent in 84%, good in 12 % and 
satisfactory in 4% of parturients who received CSEA, whereas pain relief 
was excellent in 52%, good in 32% and satisfactory in 16% of parturients 
who received EA. 
 Breakthrough pain: Occurred in 4% of parturients who received 
CSEA and in 16% of parturients who received EA. The difference was 
significant statistically (p<0.5). 
♦ In a similar study conducted by A.T. Sia et al a similar observation 
was made with the need for supplemental analgesics being greater in 
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the EA group. They have stated that induction with a spinal block as in 
CSEA produces a faster onset and more efficacious block than EA. 
CSEA cold be deemed to be superior to and more uniform than EA in 
counteracting the increased nociception that occurs as the second stage 
of labour approaches, especially with respect to the contribution of the 
perineal afferents. 
♦ David Hepner et al reported VAS score of < 3 within 5 minutes and 
the first sign of analgesia as early as 1.8(1.5) minutes, reflecting rapid 
onset of complete analgesia with CSEA over that of conventional 
epidural analgesia. 
♦ According to Roshan Fernando in article on ambulatory epidurals he 
reported that the epidural technique will have a slower onset time than 
the CSEA but both should offer equivalent analgesia after 30 minutes. 
 Similar observations were made by other authors and also in our 
study. 
AMOUNT OF BUPIVACAINE AND FENTANYL USED: 
Bupivacaine  
 Primi and multi gravidae of CSEA and EA group were comparable 
and statistically insignificant.   
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Fentanyl  
 The amount of fentanyl (in micrograms) used in CSEA group 
among both primi and multi gravidae was significantly higher than EA 
group.      
 This is due to the initial bolus dose of 25mcg fentanyl intrathecally 
and initial epidural dose of 20 mcg of fentanyl remaining a constant, 
subsequent doses were adjusted to heart rate, blood pressure and sedation. 
Whereas in the EA group only the initial bolus of 20mcg of fentanyl was 
constant, subsequent doses being titrated according to heart rate, blood 
pressure and sedation. 
 Despite the higher dose of fentanyl used in the CSEA group no 
major complications to the mother or foetus occurred and had the benefit 
of rapid and complete analgesia leading to greater parturient satisfaction. 
 
 AT Sia et al in their study reported greater parturient satisfaction in 
CSEA over EA (p < 0.026) 
 
MEAN RATE OF CERVICAL DILATATION:  
 The difference in the mean rate of cervical dilatation between the 
CSEA and EA groups was statistically insignificant. The difference in the 
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mean rate of cervical dilatation between the control group and CSEA 
group was statistically significant. The difference in the mean rate of 
cervical dilatation between the control group and the EA group was also 
statistically significant.  
  The study groups had a rapid progression of labour with good 
uterine contraction and cervical dilatation which is due to elimination of 
anxiety and pain of labour and the correction of dystocia.  
DURATION OF THE FIRST STAGE OF LABOUR:  
 The average duration of the first stage of labour in both primi and 
multi in CSEA and EA group was comparable. The average duration of 
the first stage of labour in both primi and multi in the study groups were 
significantly less than the control group. 
 Only the active stage of labour was taken into account. Women 
managed actively in labour regardless of the timing of epidural placement 
had shorter labours than controls.(Roger R et al, 1999). 
 Chestnut and associates have reported that continuous infusion of 
0.0625% bupivacaine with 2mcg of fentanyl given to primi did not 
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prolong, but tended to decrease the duration of the active phase of the first 
stage of labour compared to the general obstetric population. 
DURATION OF SECOND STAGE OF LABOUR:  
The average duration of the second stage of labour in the primi and multi 
gravidae in the CSEA and EA groups were marginally prolonged 
compared to the control group but it was not statistically significant.   
DURATION OF THIRD STAGE OF LABOUR: 
 The average duration of the third stage of labour in the primi and 
multi of the CSEA, EA and control groups were comparable statistically 
insignificant.  
TOTAL DURATION OF LABOUR: 
Primi   
 The mean total duration of labour in the CSEA group was 
180.67(67.53) minutes. The mean total duration of labour in the EA group 
was 152.33(26.38) minutes. The mean total duration of labour in the 
control group was 246.92 (24.25) minutes 
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Multi  
 The mean total duration of labour in the CSEA group was 96.46 
(28.99) minutes. The mean total duration of labour in the EA group was 
95.92(33.32) minutes. The mean total duration of labour in the control 
group was 171.53 (15.44) minutes. The total duration of labour was 
significantly shortened in the CSEA and EA groups among both primi and 
multi gravidae when compared to that of the control group.   
MODE OF DELIVERY: 
 In the CSEA and EA groups no difference in the mode of delivery 
was observed in the primi and multi groups except for that the incidence 
of instrumental delivery was higher among the primi gravidae.   
 Primi: Only 12% of primi had instrumental delivery in the control 
group which again was statistically significant when compared to those in 
CSEA and EA groups. 4% had caesarean delivery in the control group 
which was comparable to those in the CSEA and EA groups.  
 MULTI: 92% in the control group had labour naturale which was 
statistically not significant when compared with those in CSEA and EA 
groups. Only 8% had instrumental delivery in the control group which 
again was statistically not significant when compared to those in CSEA 
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and EA groups. None had caesarean delivery in the control group which 
was comparable to those in the CSEA and EA groups.  
 In the study by A.T.Sia et al no difference was detected in the mode 
of delivery between the CSEA and EA groups. 
 Nageotte and colleagues in their study comparing epidural 
analgesia with combined spinal epidural analgesia during labour in 
nulliparous women found no significant difference between the two 
groups in terms of the rate of caesarean section or the frequency of 
dystocia. 
INDICATION FOR ASSISTED DELIVERY:  
 Assisted deliveries include both forceps and lower segment 
caesarean section deliveries.  
 Primi: In the CSEA group 3 parturients underwent assisted 
delivery for failure of secondary forces, 1 parturient for prolonged second 
stage, 1 parturient for foetal distress and 1 parturient underwent caesarean 
section due to persistent occipito-posterior presentation. In the EA group 
3 parturients underwent assisted delivery due to failure of secondary 
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forces and 2 parturients for foetal distress. In the control group 2 required 
assisted delivery for failure of secondary forces.                     
 Multi: In the EA group one parturient required caesarean section 
for foetal distress and in the control group one parturient required 
caesarean delivery for foetal distress. 
 FOETAL SURVEILLANCE: 
 Foetal wellbeing was assessed using the APGAR scoring done at 1 
minute and 5 minutes from the time since birth. The mean APGAR in the 
study (CSEA, EA) and control group among both primi and multi were 
similar. 
 In a study conducted by Fernando et al (1997) there was no 
correlation between APGAR score, umbilical blood gases or 
neurobehavioral scores and umbilical venous concentration of either 
fentanyl or bupivacaine. 
SIDE EFFECTS: 
 Pruritis was the most common complication occurring during 
CSEA (96%) followed by sedation (84%). In the EA group 32% had 
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pruritis and 20% had sedation. The differences were statistically 
significant. Pruritis has an incidence of 60% with neuraxial opioid 
administration as compared to about 15 to 18% for epidural local 
anaesthetics or systemic opioids. Greater incidence of pruritis occurs 
during pregnancy. Mechanism of pruritis is considered to be due to central 
activation of the itch centre in the medulla or opioid receptors in the 
trigeminal nucleus or nerve roots with cephalad migration of the opioid..   
  Nausea and vomiting occurred in 16% of CSEA group and in 12% 
of EA group. The difference was statistically insignificant. Nausea and 
vomiting associated with neuraxial administration of single dose opioids 
occurs in approximately 20-50% of patients and the cumulative incidence 
among those receiving continuous infusions of opioids may be as high as 
45% to 80%. It may be due to the cephalad migration of the opioid within 
the CSF to the area postrema in the medulla. Use of fentanyl in 
combination with local anaesthetics is associated with lower incidence of 
nausea and vomiting when compared with infusions using morphine.                                   
 Shivering occurred in 24% of CSEA group and in 20% of EA 
group. The difference was statistically insignificant.                                                               
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 Headache occurred in 8% of CSEA group and in 4% of EA group. 
The difference was statistically insignificant.  
 Urinary retention occurred in 4% each of CSEA and EA groups.                                 
 Motor blockade occurred only in one parturient (4%) in the EA 
group which was of grade-1(modified bromage scale). 
 Backache occurred in 4% of CSEA and in 8% of control group. 
 Hypotension occurred in 12% of CSEA and in 4% of EA group.                                 
 Incidence of respiratory depression associated with neuraxial 
opioids is dose dependent and typically ranges from 0.1 to 0.9% .There 
was no instance of respiratory depression in either of the study groups.        
 A T Sia and colleagues in their study found pruritis was more 
frequent in the CSEA group. Compared with EA group, the CSEA did not 
increase the risk of postpartum headache, backache or urinary retention. 
In their study EA group was associated with a higher incidence of 
transient neurological deficits. 
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SUMMARY 
 The study involved a total of 75 parturients, 25 in the combined 
spinal epidural analgesia group (CSEA), 25 in the epidural analgesia 
group (EA) and 25 in the control group. There were 12 primi and 13 
multigravidae in each group. 
 Labour analgesia using above techniques was provided once the 
parturient entered the active phase of labour. 
 CSEA group received an initial intrathecal fentanyl 25 mcg with 
0.5ml of preservative free bupivacaine 0.25%. It was followed by 
maintenance with intermittent boluses of 10ml of 0.125% bupivacaine 
with 2mcg/ml of fentanyl hourly starting from 45 minutes after the 
intrathecal dose. 
 EA group received 10ml of 0.125%bupivacaine with 2mcg/ml of 
fentanyl hourly from the time of initiation.  
 Onset of analgesia CSEA group was a mean of 1.71 (0.33) minutes 
in primi and 1.38 (0.36) minutes in multi as against a mean of 5.25 (1.36) 
minutes in primi and 4.46 (1.05) minutes in multi in EA group. There was 
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a significant difference in the onset times with the CSEA group having 
rapidity of analgesic onset as early as 1 minute post block.  
 Labour analgesia was excellent in 84% of parturients, good in 12% 
and satisfactory in 4% in CSEA group as opposed to 52% excellent, 32% 
good and 16% satisfactory response in EA Group. 
 The mean rate of cervical dilatation was comparable in both the 
groups. The mean duration of first, second and third stages of labour 
among primi and multi in CSEA and EA group were comparable and not 
statistically significant. When compared to the control group there was 
significantly greater rate of cervical dilatation leading to rapid progression 
of first stage of labour in the study group. The average duration of second 
stage of labour was marginally prolonged in the study groups when 
compared to the control group but were statistically insignificant. The 
average duration of the third stage of labour was comparable between the 
study and control groups. There was a significant reduction in the total 
duration of labour in the CSEA & EA groups when compared to the study 
group.     
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 The mean amount of bupivacaine used in primi and multigravidae 
in CSEA and EA group were similar and not statistically significant. The 
mean amount of fentanyl used in primi and multigravidae in CSEA group 
was higher when compared to the amount used in EA group in both primi 
and multigravidae but with no major side effects to the mother or foetus. 
 CSEA was associated with greater parturient satisfaction. 
 The mode of delivery was comparable between CSEA and EA 
among both primi and multigravidae. The difference in the mode of 
delivery was statistically insignificant between the two groups. 
 The incidence of instrumental delivery was higher in primipara of 
both CSEA and EA groups when compared to control. 
 First minute Apgar scores in the neonate was 6.8(0.7) and 
6.56(0.65) in the CSEA and EA groups respectively. 5th minute Apgar 
score in the neonate was 8.56(0.58) and 8.36(0.57) in the CSEA and EA 
groups respectively. The results were not statistically significant. 
 Pruritis was the most frequently reported side effect with CSEA 
followed by nausea, vomiting and sedation. These were statistically 
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higher than those observed in EA group. Pruritis was mild and short lived 
requiring no intervention. Other side effects like headache, shivering, 
hypotension were observed to a lesser and comparable extent among both 
CSEA and EA groups. There were no major maternal or foetal 
complications with either CSEA or EA techniques. 
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CONCLUSION 
 Combined spinal epidural analgesia with fentanyl – bupivacaine 
combination is associated with greater parturient satisfaction due to its 
rapidity of onset providing complete pain relief in 1.54minutes on an 
average. The quality of pain relief was excellent in 84% of parturients 
with very less requirement for supplemental analgesics. In the above 
respect CSEA was far superior compared to EA. 
 CSEA has a favourable outcome on the progress of labour. It 
augments cervical dilatation and shortens the first stage of labour by 
producing good co-ordinated uterine contractions at regular intervals. The 
duration of the second stage of labour was prolonged without any 
maternal or foetal complications. Neonatal outcome was favourable as 
evidenced by the 1minute and 5 minute APGAR scores. The above effects 
were comparable to conventional group. 
 Though the incidence of pruritis, sedation, nausea and vomiting 
were higher they were either transient or mild requiring no intervention. 
No major maternal or foetal complications occurred reflecting the safety 
profile of a properly conducted CSEA. 
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  Combined spinal epidural analgesia with fentanyl – bupivacaine 
combination is thus a safe and better alternative to EA as a technique of 
neuraxial block for effective labour analgesia. 
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PROFORMA  
 
COMPARISON OF COMBINED SPINAL EPIDURAL ANALGESIA 
WITH EPIDURAL ANALGESIA USING FENTANYL- BUPIVACAINE 
COMBINATION FOR EFFECTIVE LABOUR ANALGESIA 
 
 
 
Date         S.No  
        CSEA/ EA/Control No.   
        IP.No  
        Unit  
        Obstetric Assistant   
Name  
 
Age  
Height        Anesthesiology  Asst  
Weight        Parity  
History  
 
Basic Investigations  
 
 O/E    Maternal    Fetal  
    General condition   Heart rate   
    CVS 
    RS 
    CNS 
    P/A 
    P/V 
 
 
  Pre Block   Maternal    Fetal  
  Pulse Rate      Heart Rate  
  Blood Pressure  
  SpO2 
  Respiratory Rate  
  Cervical Dilatation  
  Pain Score  
  Oxytocin Use  
Block  
 Technique   
 
 Start Time  
 Problems  
First Dose  
 Time   PR  BP  SpO2  RR  FHR 
 
 Uterine Activity 
 Pain relief – Score  
 Motor Block  
 Sedation Score 
 Other adverse reactions (Time and Intervention)   
 Labour Progress  
 Obstetric intervention  
Top Up 1  
 Time   PR  BP  SpO2  RR  FHR 
 
 Uterine Activity 
 Pain relief – Score  
 Motor Block  
 Sedation Score 
 Other adverse reactions (Time and Intervention)   
 Labour Progress  
 Obstetric intervention  
 
Top up II 
 Time   PR  BP  SpO2  RR  FHR 
 
 Uterine Activity 
 Pain relief – Score  
 Motor Block  
 Sedation Score 
 Other adverse reactions (Time and Intervention)   
 Labour Progress  
 Obstetric intervention  
Further Top ups were recorded in a similar manner as above.  
 
Delivery  
 Time  
 Mode  
 Episiotomy  
 Monitoring  
 
 Duration  
  I stage  
  II stage  
 
 
Follow up   Maternal    Fetal  
 Headache       Birth Weight  
 Transient Neurological deficit    APGAR – 1 minute 
                5 minute   
 Urinary retention 
 Overall parturient satisfaction  
Queen Victoria 
(born 1819, reigned 1839 - 1901) 
 
 
 
 
"Doctor Snow gave that blessed chloroform and the effect 
was soothing, quieting, and delightful beyond measure." 
 
Professor James Young Simpson 
(1811 – 1870) 
 
 
 
 
"All pain is per se and especially in excess, destructive 
and ultimately fatal in its nature and effects."  
 
 
 
 
 
 
PATHWAYS OF LABOUR PAIN AND TYPES OF BLOCKS 
FOR PAIN RELIEF  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mc Gills Pain Rating Index - Scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANATOMY OF SPINAL – EPIDURAL SPACE  
 
 
 
 
 
 
 
 
 
 
VISUAL ANALOGUE SCALE  
Pain Score  
 
 
 
 
VAS   QUALITY OF ANALGESIA  
0-2 Excellent  
3-4 Good  
4-6 Satisfactory  
6-8 Slight 
  8-10   No relief   
 
 
 
 
 
 
 
 
DISTRIBUTION AND INTENSITY OF LABOUR PAIN DURING 
EACH STAGE OF LABOUR AND DELIVERY  
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSEQUENCES OF UNRELIEVED PAIN IN LABOUR 
 
 
 
 
 
 
 
 
 
 
 
BUPIVACAINE STRUCTURAL FORMULA  
 
 
 
 
 
 
 
 
 
 
 
FENTANYL STRUCTURAL FORMULA  
 
 
 
 
AGE DISTRIBUTION: 
Age in years 
CSEA EA 
 
Category 
Mean S.D. Mean S.D. 
 
‘p’ 
Primi 22.58 2.19 22.08 2.39 0.5799 
Not significant 
Multi 25.15 3.8 25.85 2.85 0.518 
Not significant 
 
Age in years 
CSEA CONTROL 
 
Category 
Mean S.D. Mean S.D. 
 
‘p’ 
Primi 22.58 2.19 23.16 3.30 0.5801 
Not significant 
Multi 25.15 3.8 25.72 3.38 0.522 
Not significant 
 
 
Age in years 
EA CONTROL 
 
Category 
Mean S.D. Mean S.D. 
 
‘p’ 
Primi 22.08 2.39 23.16 3.30 0.6123 
Not significant 
Multi 25.85 2.85 25.72 3.38 0.5231 
Not significant 
 
 
HEIGHT, WEIGHT CHARACTERISTICS: 
 
CSEA EA Parameter 
Mean S.D. Mean S.D. 
 
‘p’ 
Height (in cms) 
Primi 
Multi 
 
152.67 
153.38 
 
5.91 
6.09 
 
154.33
154.69
 
5.42 
4.4 
 
0.2123 (Not significant) 
0.4241(Not significant) 
Weight (in kgs) 
Primi 
Multi 
 
55.75 
61.69 
 
10.91 
7.17 
 
56.33 
62.15 
 
10.85 
7.85 
 
0.8848 (Not significant) 
0.8357(Not significant) 
 
 
CSEA CONTROL  Parameter 
Mean S.D. Mean S.D. 
 
‘p’ 
Height (in cms) 
Primi 
Multi 
 
152.67 
153.38 
 
5.91 
6.09 
 
151.80
153.04
 
6.6 
4.64 
 
0.4217(Not significant) 
0.6721(Not significant) 
Weight (in kgs) 
Primi 
Multi 
 
55.75 
61.69 
 
10.91 
7.17 
 
55.52 
54.68 
 
4.37 
6.13 
 
0.8912 (Not significant) 
0.2017(Not significant) 
 
 
 
 
EA CONTROL  Parameter 
Mean S.D. Mean S.D. 
‘p’ 
Height (in cms) 
Primi 
Multi 
 
154.33 
154.69 
 
5.42 
4.40 
 
151.80
153.04
 
6.6 
4.64 
 
0.1821(Not significant) 
0.4210(Not significant) 
Weight (in kgs) 
Primi 
Multi 
 
56.33 
62.15 
 
10.85 
7.85 
 
55.52 
54.68 
 
4.37 
6.13 
 
0.7612(Not significant) 
0.0714(Not significant) 
 
 
 
 
RATE OF CERVICAL DILATATION: 
 
Rate of Cervical Dilatation (in cms) 
CSEA EA 
 
Category 
Mean S.D. Mean S.D. 
 
‘p’ 
Primi 3.42 0.38 4.22 0.52 0.2248 
Not significant 
Multi 5.97 0.58 6.03 0.62 0.8776 
Not significant 
 
Rate of Cervical Dilatation (in cms) 
CSEA CONTROL 
 
Category 
Mean S.D. Mean S.D. 
 
‘p’ 
Primi 3.42 0.38 1.63 1.04 0.021 
Significant 
Multi 5.97 0.58 2.00 1.01 0.014 Significant 
 
 
Rate of Cervical Dilatation (in cms) 
EA CONTROL 
 
Category 
Mean S.D. Mean S.D. 
 
‘p’ 
Primi 4.22 0.52 1.63 1.04 0.0061 Significant 
Multi 6.03 0.62 2.00 1.01 0.0093 Significant 
 
 
  
 
 
 
AMOUNT OF DRUGS USED: 
 
CSEA EA Drug 
Mean S.D. Mean S.D. 
 
‘p’ 
Bupivacaine (mg) 
Primi 
Multi 
 
31.83 
17.86 
 
15.76
6.54 
 
32.92 
22.5 
 
6.11 
6.85 
 
0.3845(Not significant) 
0.2636(Not significant) 
Fentanyl (µcg) 
Primi 
Multi 
 
74.3 
50.23 
 
25.25
8.85 
 
52.67 
36.00 
 
9.77 
10.95 
 
0.0017 (Significant) 
0.0001(Significant) 
 
 
 
 
 
TOTAL NO OF TOP UPS GIVEN: 
 
Number of top ups 
CSEA EA 
 
 
Category Mean S.D. Mean S.D. 
 
‘p’ 
Primi 2.5 1.24 2.83 0.58 0.0413(Significant) 
Multi 1.38 0.51 1.85 0.55 0.0407 (Significant) 
 
 
 
ONSET OF PAIN RELIEF: 
 
Onset of pain relief ( in minutes) 
CSEA EA 
 
Category 
Mean S.D. Mean S.D. 
‘p’ 
Primi 1.71 0.33 5.25 1.36 0.0001( Significant) 
Multi 1.38 0.36 4.46 1.05 0.0001(Significant) 
Total 1.54 0.38 4.84 1.25 0.0001(Significant) 
 
 
 
 
 
QUALITY OF PAIN RELIEF: 
CSEA EA Visual Analogue Scale 
 Mean S.D. Mean S.D. 
 
‘p’ 
Initial 45 minutes 
Primi 
Multi 
Total 
 
 
0.31 
0.15 
0.23 
 
 
0.18 
0.15 
0.18 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
After first 45 minutes 
Primi 
Multi 
Total 
 
 
2.47 
0.83 
1.61 
 
 
1.4 
0.32 
1.28 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
Total average 
Primi 
Multi 
Total 
 
 
1.4 
0.51 
0.94 
 
 
0.73 
0.24 
0.69 
 
 
2.54 
1.27 
1.88 
 
 
0.97 
0.6 
1.01 
 
 
0.0022 Significant 
0.0005 Significant 
0.0003 Significant 
 
 
 
 
 
BREAKTHROUGH PAIN:                                                                                                  
 
CSEA EA Break through pain 
No. % No. % 
Present 1 4 4 16 
Absent 24 96 21 84 
Total 25 100 25 100 
 p = 0.032, significant  
 
 
SENSORY LEVEL: 
 
CSEA EA Sensory Level 
No. % No. % 
T6 5 20 3 12 
T7 - - - - 
T8 15 60 18 72 
T9 - - - - 
T10 5 20 4 16 
Total 25 100 25 100 
 
 
DURATION OF LABOUR: 
Duration of labour (in minutes)  
CSEA EA 
 
Stage 
Mean S.D. Mean S.D. 
 
‘p’ 
Stage I 
Primi 
Multi 
 
122.92 
70.38 
 
45.8 
23.98 
 
99.6 
69.63 
 
15.20 
25.84 
 
0.1482 (Not significant) 
0.7973(Not significant) 
Stage II 
Primi 
Multi 
 
51.5 
21.46 
 
24.97 
5.29 
 
46.67 
23.46 
 
11.02 
8.06 
 
0.8618 (Not significant) 
0.7799(Not significant) 
Stage III 
Primi 
Multi 
 
 
 
6.82 
4.62 
 
 
 
 
1.66 
 
0.96 
 
 
 
6.7 
3.85 
 
 
 
1.4 
1.28 
 
 
 
0.361(Not significant) 
0.0503(Not Significant) 
 
Total duration 
Primi 
Multi 
 
 
180.67 
96.46 
 
 
67.53 
28.99 
 
 
152.33
95.92 
 
 
26.38 
33.32 
 
 
0.3122(Not significant) 
0.9653(Not significant) 
 
 
 
 
 
 
 
DURATION OF LABOUR: 
Duration of labour (in minutes)  
CSEA CONTROL 
 
Stage 
Mean S.D. Mean S.D. 
 
‘p’ 
Stage I 
Primi 
Multi 
 
122.92 
70.38 
 
45.8 
23.98 
 
201.47
145 
 
57.78 
38.83 
 
0.0011 (Significant) 
0.0023 (Significant) 
Stage II 
Primi 
Multi 
 
51.5 
21.46 
 
24.97 
5.29 
 
37.85 
20.76 
 
20.9 
12.8 
 
0.3170 (Not significant) 
0.5374 (Not significant) 
Stage III 
Primi 
Multi 
 
 
 
6.82 
4.62 
 
 
 
 
1.66 
 
0.96 
 
 
 
7.6 
5.76 
 
 
 
3.3 
2.4 
 
 
 
0.7832 (Not significant) 
0.6914 (Not Significant) 
 
Total duration 
Primi 
Multi 
 
 
180.67 
96.46 
 
 
67.53 
28.99 
 
 
246.92
171.53
 
24.25 
15.44 
 
 
0.0097 (Significant) 
0.0063 (Significant) 
 
 
 
 
 
 
DURATION OF LABOUR: 
 
Duration of labour (in minutes)  
EA CONTROL 
 
Stage 
Mean S.D. Mean S.D. 
 
‘p’ 
Stage I 
Primi 
Multi 
 
99.6 
69.63 
 
15.20 
25.84 
 
201.47
145 
 
57.78 
38.83 
 
0.0027 (Significant) 
0.0013 (Significant) 
Stage II 
Primi 
Multi 
 
46.67 
23.46 
 
11.02 
8.06 
 
37.85 
20.76 
 
20.9 
12.8 
 
0.0793 (Not significant) 
0.1021 (Not significant) 
Stage III 
Primi 
Multi 
 
 
 
6.7 
3.85 
 
 
 
1.4 
 
1.28 
 
 
7.6 
5.76 
 
 
 
3.3 
2.4 
 
 
 
0.0925 (Not significant) 
0.0839 (Not Significant) 
 
Total duration 
Primi 
Multi 
 
 
152.3 
95.92 
 
26.38 
33.32 
 
 
246.92
171.53
 
24.25 
15.44 
 
 
0.0031 (Significant) 
0.0019 (Significant) 
 
 
 
 
 
MODE OF DELIVERY: 
CSEA EA CONTROL  Mode of delivery 
No. % No. % No. % 
Primi 
Labour Natural 
LMC 
Outlet 
Instrumental Total 
Caesarean 
Total 
 
 
6 
2 
3 
5 
1 
12 
 
 
50.0 
16.7 
25.0 
41.7 
8.3 
100 
 
 
6 
2 
4 
6 
- 
12 
 
 
50.0 
16.7 
33.3 
50.0 
- 
100 
 
 
10 
- 
1 
1 
- 
12 
 
 
83.3 
- 
8.3 
8.3 
- 
100 
Multi 
Labour Natural 
LMC 
Outlet 
Instrumental Total 
Caesarean 
Total 
 
 
13 
- 
- 
- 
- 
13 
 
 
100 
- 
- 
- 
- 
100 
 
 
12 
- 
1 
1 
- 
13 
 
 
92.3 
- 
7.7 
7.7 
- 
100 
 
 
12 
- 
1 
1 
- 
13 
 
 
92.3 
- 
7.69 
7.69 
- 
100 
 
 
 
INDICATIONS FOR ASSISSTED DELIVERY: 
CSEA EA CONTROL  
Indication 
No. No. No. 
Failure of 
secondary forces 
3 5 1 
Fetal distress 1 2 1 
Prolongation of II 
Stage 
1 - - 
ROP – Non 
progression and 
fetal distress 
1 - - 
Total no requiring 
assistance  
6 7 2 
Nil assistance 
required 
19 18 23 
 
 
 
 
 
APGAR SCORE: 
 
CSEA EA Apgar Score 
No. % No. % 
1 minute 
Mean 
S.D. 
 
6.8 
0.7 
 
6.56 
0.65 
‘p’ 0.0888 (Not significant) 
5th minute  
Mean 
S.D. 
 
8.56 
0.58 
 
8.36 
0.57 
‘p’ 0.1869 (Not significant) 
 
CSEA CONTROL   
Apgar Score No. % No. % 
1 minute 
Mean 
S.D. 
 
6.8 
0.7 
 
6.75 
0.6 
‘p’  (Not significant) 
5th minute  
Mean 
S.D. 
 
8.56 
0.58 
 
8.4 
0.61 
‘p’ (Not significant) 
 
EA CONTROL   
Apgar Score No. % No. % 
1 minute 
Mean 
S.D. 
 
6.56 
0.65 
 
6.75 
0.6 
‘p’  (Not significant) 
5th minute  
Mean 
S.D. 
 
8.36 
0.57 
 
8.4 
0.61 
‘p’ (Not significant) 
 
COMPLICATIONS: 
 
CSEA EA CONTROL Complications 
No. % No. % No. % 
Pruritis 
Present 
Absent 
 
24 
1 
 
96 
4 
 
8 
17 
 
32 
68 
 
 
 
 
 
 
 
‘p’ 0.0001 ( Significant) 
Shivering 
Present 
Absent 
 
 
6 
19 
 
24 
76 
 
5 
20 
 
20 
80 
 
 
1 
24 
 
 
4 
96 
‘p’ 0.2087 (Not significant) 
Sedation 
Present (25- Score 2 
               1 - score 1)  
Absent 
 
21 
 
4 
 
84 
 
16 
 
5 
 
20 
 
20 
 
80 
 
 
 
 
 
 
‘p’ 0.0001 ( significant) 
Nausea 
Present 
Absent 
 
 
4 
21 
 
16 
84 
 
3 
22 
 
12 
88 
 
 
 
 
 
 
‘p’ 0.1173 (Not significant) 
Vomiting  
Present 
Absent 
 
3 
22 
 
12 
88 
 
3 
22 
 
12 
88 
 
 
 
 
 
 
‘p’ 0.0063 ( Significant) 
Headache   
Present 
Absent 
 
2 
23 
 
8 
92 
 
1 
24 
 
4 
96 
 
 
 
 
 
 
‘p’  
Backache  
Present 
Absent 
 
1 
24 
 
4 
96 
 
2 
23 
 
8 
92 
 
 
2 
23 
 
 
8 
92 
‘p’  
Urinary retention  
Present 
Absent 
 
1 
24 
 
4 
96 
 
1 
24 
 
4 
96 
 
 
2 
23 
 
 
8 
92 
‘p’  
Hypotension  
Present 
Absent 
 
3 
22 
 
12 
88 
 
4 
21 
 
16 
84 
 
 
2 
23 
 
 
8 
92 
‘p’  
Motor blockade  
Present (Modf.bromage I) 
Absent 
 
- 
- 
 
- 
- 
 
1 
24 
 
4 
96 
 
 
- 
- 
 
 
- 
- 
‘p’  
Respiratory depression  
Present 
Absent 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
‘p’  
 
 
 
 
PAIN IN LABOUR : PATHWAYS & MECHANISMS 
Site of origin Characteristic Stimulus Neural involvement Localization 
Uterus  Contraction -? 
Ischemic? Plus acute 
stretch  
Sympathetic out flow, 
root values T11/T12 
spreading to T10 & L1 
Referred to anterior 
rami of somatic roots; 
upper abdominal wall 
anteriorly down to 
groin; inner aspects 
upper thighs.  
Peri-uterine tissues 
mainly posterior  
Pressure-either with 
contraction or persistent. 
Usually associated with 
foetal malposition or 
unusual conformation of 
sacrum   
Somatic roots of lumbo 
– sacral plexus  
Distribution of 
posterior low and mid 
back; also back of 
thighs  
Lower birth canal Distention of vagina and 
perineum in second stage 
Somatic roots S2/3/4 Accurate to site of 
stimulus- not referred  
Bladder  Over- distension; can be 
persistent or felt during 
contraction   
Sympathetic T11-? L2 
via hypogastric plexus, 
parasympathetic  
Usually supra pubic 
only; rarely referred to 
distribution of somatic 
sacral roots. 
Myometrium and 
uterine visceral 
peritoneum  
Abruption; scar dehiscence T10 – L1 Accurate to surface 
marking of site of 
pathology.   
 
 
 
 
